Novartis posts Q2 sales growth, reaffirms 2026 guidance
Net sales rose 1% in constant currencies and 3% in USD in Q2; core operating income was flat and full-year guidance was reaffirmed.
Mateo Fernandez ·
Novartis reported second-quarter results on July 21, 2026: net sales rose 1% in constant currencies and 3% in US dollars, officials said. Core operating income was flat in both constant-currency and US-dollar terms, and the company said it reaffirmed full-year guidance.
Q2 sales, core income
The company said sales growth was supported by continued uptake in key markets and that it had further advanced its clinical pipeline during the quarter. Data showed management kept its full-year targets unchanged despite the modest top-line increase.
Analysts and investors will have immediate things to parse: margin stability, pipeline progress, and whether guidance leaves room for upgrades. Officials said details on regional performance and product-level drivers were provided in the ad hoc announcement; market participants will use those line items to refresh earnings models.
Expect trading activity and analyst notes over the coming session. Look for updated consensus estimates and broker reactions by July 22, 2026, as investors digest the split between modest sales growth and unchanged core operating profit.